What's New

Alliance Asks for Inclusion of Pediatric Oncology Provision in PREA Reauthorization

13 Apr 2012 1:37 PM | Amanda Schwartz (Administrator)
In a letter to Rep. Anna Eshoo (D-CA) and Rep. Mike Rogers (R-MI), co-sponsors of the reauthorization of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), the Alliance asked for the reauthorization of the PREA to include a provision to assist in the development of pediatric oncology drugs. In order to strengthen the requirement that new drugs should be studied in children with cancer, the Alliance urges Congress to adopt a modifying proposal that could allow for the conduct of pediatric oncology studies when a relevant target or pathway is explicitly included in the product label for a new adult oncology drug.
 

Alliance for Childhood Cancer

2318 Mill Road
Alexandria, VA 22314
Telephone (571) 483-1670
alliance@asco.org

Powered by Wild Apricot Membership Software